Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

AstraZeneca Signs $150 Million China Deal with Ironwood Pharma

publication date: Oct 23, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca signed a $150 million deal with Ironwood Pharmaceuticals to co-develop and co-commercialize Ironwood's novel constipation treatment in China. Linaclotide, a guanylate cyclase-C (GC-C) agonist, was approved by the US FDA in August to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. In May, Ironwood announced a Phase III trial of the drug in China. More details....

Stock Symbols: (NYSE: AZN) (NSDQ: IRWD)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors